Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAT2A | P31153 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.38 |
| ▸ | PARP1 | P09874 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.34 |
| ▸ | GABRD | O14764 | 1/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.34 |
| ▸ | GABRE | P78334 | 1/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542581 | 0.76 | HAVCR2 (0.34) | MAT2A | |
| SCHEMBL30762814 | 0.76 | HAVCR2 (0.34) | MAT2A | |
| SCHEMBL26828704 | 0.74 | MAOA (0.43) | MAPT | |
| SCHEMBL22781173 | 0.73 | ALDH1A1 (0.32) | PDE4APDE4BPDE4CPDE4DKDM4E | |
| SCHEMBL30736415 | 0.72 | CYP1A2 (0.44) | MAT2APARP1CYP1A2GABRPGABRD | |
| SCHEMBL22781102 | 0.72 | KMT2A (0.32) | PDE4APDE4BPDE4CPDE4DMAPT | |
| SCHEMBL29458522 | 0.70 | POLB (0.64) | MAT2APARP1CYP1A2POLBHPGD | |
| SCHEMBL14227440 | 0.70 | POLB (0.64) | MAT2APARP1CYP1A2POLBHPGD | |
| SCHEMBL9836581 | 0.68 | MAT2A (0.61) | MAT2AGAAKDM4E | |
| SCHEMBL31205780 | 0.68 | KDM4E (0.46) | PARP1POLBHPGDGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | MAT2A 2797/4885MET 689/4885PARP1 1522/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAT2A 2797/4885MET 689/4885PARP1 1522/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | MAT2A 2797/4885MET 689/4885PARP1 1522/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | MAT2A 2797/4885MET 689/4885PARP1 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.